3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
8
Neoplasm Metastasis
7
Multiple Myeloma
6
Prostatic Neoplasms
5
Pain
3
Uterine Cervical Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bone Neoplasms
2
Uterine Cervical Dysplasia
1
Urologic Neoplasms
1
Small Cell Lung Carcinoma
1
Precancerous Conditions
1
Pleural Effusion, Malignant
1
Osteoporosis
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm, Residual
1
Lung Neoplasms
1
Kidney Neoplasms
1
Humoral Hypercalcemia Of Malignancy
1
Hematologic Neoplasms
1
Giant Cell Tumors of Bone
1
Giant Cell Tumor of Bone
1
Disease Progression
1
Carcinoma, Ductal, Breast
1
Breast Neoplasms, Male
1
Bone Diseases, Metabolic
1
Adenocarcinoma
1
Interventions
blinatumomab
3
Cytarabine
2
Cyclophosphamide
2
Azacitidine
2
venetoclax
1
sabatolimab
1
ruxolitinib
1
pulrodemstat besilate
1
pembrolizumab
1
peginterferon alfa-2a
1
nilotinib
1
fludarabine
1
daratumumab
1
Zoledronic Acid
1
Vitamin D
1
Methotrexate
1
Imatinib Mesylate
1
GNKG168
1
Dasatinib
1
Clofarabine
1
Celecoxib
1
Calcium
1
CD3 Complex
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasm, Residual
×
Zoledronic Acid
×
Clear all
NCT00172068
2009-12-23
MRD-1
Novartis
Phase 2
Terminated
96 enrolled